Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study by Jindong Sheng, Haitao Luo, Xiangyu Liu, Chunyan Liu, Wenhao Zhou, Yujie Zhao, Ruoyan Liu, Dan Li, Changxiao Xu, Bo Yang, Ying Liu, Xin Fu, Lewen Bao, Ke Wang, Jihui Hao, Wenxin Liu

Get full text